Functional Target Validation for Alzheimer's Disease-Related Dementias

The National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. Department of Health and Human Services, has released a forecasted funding opportunity aimed at advancing research for Alzheimer’s Disease–Related Dementias (ADRD). The grant opportunity, titled “Functional Target Validation for Alzheimer’s Disease-Related Dementias,” seeks to support in-depth, functional validation of therapeutic target candidates. NINDS recognizes that a primary obstacle to effective ADRD treatment is the lack of well-validated biological targets. Despite advancements in basic neuroscience, translational research frequently stalls due to the insufficient rigor of early-stage target validation. This initiative, therefore, focuses on reducing the risk of translational failure and improving the probability of clinical success by confirming a causal relationship between a candidate target’s modulation and its physiological or pathological effects. This forecasted grant anticipates using a phased funding structure, potentially an R61/R33 mechanism. The first phase of funding would enable researchers to develop and optimize tools, models, and methodologies to modulate selected targets. This may include developing in vitro systems, in vivo models, or advanced technologies tailored to the disease context. In this phase, a strong emphasis will be placed on demonstrating technical feasibility and achieving specific, milestone-driven goals. Once the predefined criteria are met, the second phase will support broader cross-validation activities. These may include expanding testing across different experimental platforms, using multiple modalities, and ensuring reproducibility across independent laboratories, all of which align with NIH's guidelines for scientific rigor and transparency. The total estimated program funding for this opportunity is $1.8 million, with two anticipated awards. However, specific amounts for the award ceiling and floor have not been published in this forecast. This funding is discretionary and does not require cost sharing or matching. Eligible applicants include a wide range of U.S.-based entities such as state and local governments, tribal organizations, public and private institutions of higher education, nonprofits, and for-profit organizations. Notably, non-domestic (foreign) institutions are not eligible. Additionally, organizations such as faith-based entities, regional organizations, and agencies of the federal government are permitted to apply, highlighting the inclusivity and broad outreach of this initiative. As this is a forecasted opportunity, applications are not currently being solicited. NINDS has provided this notice in advance to allow potential applicants time to plan and assemble the necessary interdisciplinary collaborations. The estimated post date is May 5, 2026, with applications expected to be due by November 6, 2026. Award decisions may be announced around June 14, 2027, with projects anticipated to begin as early as July 1, 2027. These estimates offer a useful timeline for institutions to prepare their scientific and administrative materials in alignment with the submission window. The grant’s focus on validating therapeutic targets through rigorous, evidence-based methodologies aims to bridge the translational gap between discovery and clinical application. By ensuring that targets are robustly characterized and linked to relevant disease processes, the initiative intends to pave the way for future therapies that are more likely to succeed in clinical trials. Interested applicants are encouraged to monitor Grants.gov and NIH notices for the formal funding announcement. Any inquiries in the meantime may be directed to the NINDS DTR ADRD contact at [email protected].